PURPOSE To evaluate the influence of a ranibizumab treatment on microaneurysm (MA) turnover in diabetic retinopathy. METHODS Sixty-nine eyes were included in this retrospective study. We compared a group of 33 eyes with ranibizumab treatment for diabetic macular edema to 36 eyes with nonproliferative diabetic retinopathy only. Nonmydriatic ultra-widefield scanning laser ophthalmoscopy (Optomap) images were obtained at a mean 4.76 ± 1.69 days prior to the first ranibizumab injection (baseline) and again 35.94 ± 2.44 days after the third consecutive injection in a 4-week interval. In untreated controls, images were obtained at baseline and 97.81 ± 3.16 days thereafter. Images were analyzed using the RetmarkerDR software (Critical Health SA, C...
Objective To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibi...
PURPOSE: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oed...
Aims: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for ...
PURPOSE To evaluate the influence of a ranibizumab treatment on microaneurysm (MA) turnover in diabe...
PurposeTo assess the effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity when ...
PURPOSE To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular ...
PurposeTo evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved wi...
PurposeTo investigate the influence of glycosylated hemoglobin (HbA1c) on treatment outcomes in pati...
Background: The aim of this study was to compare the therapeutic effect of intravitreal treatment wi...
PurposeTo evaluate the effect of monthly intravitreal ranibizumab on hard exudate (HE) area and the ...
PurposeTo determine whether early visual acuity response to ranibizumab in diabetic macular edema is...
Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there h...
Analysis of retinal microaneurysm turnover (MAT) has been previously shown to contribute to the iden...
BACKGROUND/OBJECTIVES: This post hoc analysis explores the relationship between residual oedema expo...
OBJECTIVE To evaluate the 2-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular ed...
Objective To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibi...
PURPOSE: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oed...
Aims: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for ...
PURPOSE To evaluate the influence of a ranibizumab treatment on microaneurysm (MA) turnover in diabe...
PurposeTo assess the effects of intravitreal ranibizumab on diabetic retinopathy (DR) severity when ...
PURPOSE To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with macular ...
PurposeTo evaluate the effect of systemic factors on best-corrected visual acuity (BCVA) achieved wi...
PurposeTo investigate the influence of glycosylated hemoglobin (HbA1c) on treatment outcomes in pati...
Background: The aim of this study was to compare the therapeutic effect of intravitreal treatment wi...
PurposeTo evaluate the effect of monthly intravitreal ranibizumab on hard exudate (HE) area and the ...
PurposeTo determine whether early visual acuity response to ranibizumab in diabetic macular edema is...
Purpose: Diabetic macular edema can be refractory to multiple treatment modalities. Although there h...
Analysis of retinal microaneurysm turnover (MAT) has been previously shown to contribute to the iden...
BACKGROUND/OBJECTIVES: This post hoc analysis explores the relationship between residual oedema expo...
OBJECTIVE To evaluate the 2-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular ed...
Objective To evaluate long-term efficacy and safety profiles during 3 years of individualized ranibi...
PURPOSE: Antivascular endothelial growth factor agents are increasingly used in diabetic macular oed...
Aims: To describe baseline characteristics and visual outcome for eyes treated with ranibizumab for ...